Exploring and Establishment of Combined Extracorporeal Life Support(CELS) in Critically Ill Children

Sponsor
Guoping Lu (Other)
Overall Status
Withdrawn
CT.gov ID
NCT03654287
Collaborator
Shanghai Children's Hospital (Other), Shanghai Children's Medical Center (Other), Xinhua Hospital, Shanghai Jiao Tong University School of Medicine (Other)
0
1
36
0

Study Details

Study Description

Brief Summary

Multiple organ failure (MODS) is still the leading cause of death in children in ICU. The treatment of MODS is mainly organ function monitoring and organ replacement therapy. Life support technology in vitro mainly includes mechanical ventilation, continuous renal replacement therapy (CRRT), non-biological artificial liver and extracorporeal membrane oxygenation technology (ECMO). However, critically ill patients who have multiple organ failure often require multiple organ support meanwhile. Combined extracorporeal life support (CELS) is still in its infancy to be applied in the treatment of critical illness due to nonstandard technology and theory without key breakthroughs and evidence-based medicine in the treatment of severe children organ failure.Solving the system problems supported by CELS can effectively reduce the mortality and disability rate of critically ill children and enhance health care in Shanghai, even across China.

Condition or Disease Intervention/Treatment Phase
  • Other: Treatment

Detailed Description

The whole study is described below. To investigate the timing ,curative effect and mode of CRRT and ECMO treatment for critically ill children,we choose sepsis children especially those who are combined with septic shock as research object.

Furthermore,refractory shock is the therapeutic indications of ECMO. According to their clinical manifestation and severity of the disease,they are treated by CRRT or/with ECMO in a non-randomized way.

Comparing the laboratory index and prognosis of critically ill children treated by CRRT and those treated by ECMO,we aim to investigate the the timing ,curative effect of ECMO in the treatment of septic shock especially refractory shock.

The critically ill children who treated by CRRT are divided into three groups according to their treatment mode of CRRT. The laboratory index and prognosis are also be compared to investigate curative effect of CRRT in the treatment of septic shock.

The study also include severe sepsis children without CRRT or ECMO treatment as a control group.

Study Design

Study Type:
Observational [Patient Registry]
Actual Enrollment :
0 participants
Observational Model:
Case-Control
Time Perspective:
Prospective
Official Title:
Exploring and Establishment of Multiple Organ Support Therapy(CELS)in Critically Ill Children
Anticipated Study Start Date :
Oct 30, 2018
Anticipated Primary Completion Date :
Oct 30, 2020
Anticipated Study Completion Date :
Oct 30, 2021

Arms and Interventions

Arm Intervention/Treatment
Treatment with CPFA

The critically ill children who treated by CRRT and CRRT mode is decide as CPFA.

Other: Treatment
The CELS way to intervene severe sepsis and refractory shock

Treatment with TPE+CVVHDF

The critically ill children who treated by CRRT and CRRT mode is decide as TPE+CVVHDF.

Other: Treatment
The CELS way to intervene severe sepsis and refractory shock

Treatment with CVVHDF

The critically ill children who treated by CRRT and CRRT mode is decide as CVVHDF.

Other: Treatment
The CELS way to intervene severe sepsis and refractory shock

Treatment without CRRT/ECMO

The critically ill children who are not treated by CRRT or ECMO.

Treatment with ECMO

The critically ill children who are treated by ECMO whether treated by CRRT

Other: Treatment
The CELS way to intervene severe sepsis and refractory shock

Outcome Measures

Primary Outcome Measures

  1. survival rate [28 days]

    The survival rate of children in 28 days after their hospital discharged.

Secondary Outcome Measures

  1. Pediatric Risk of Mortality score (PRISM III) [the first 24 hours after admitted to PICU]

    The PRISM score is a quantification of physiologic status using predetermined physiologic variables and their ranges that use categorical variables to facilitate accurate estimation of mortality risk.The PRISM components were separated into cardiovascular (heart rate, systolic blood pressure, and temperature), neurologic ( pupillary reactivity and mental status), respiratory (arterial Po2, pH, Pco2, and total bicarbonate), chemical (glucose, potassium, blood urea nitrogen, and creatinine), and hematologic (WBC count, platelet count, prothrombin, and partial thromboplastin time) component.The score above 10 indicates a poor prognosis and higher mortality of critical ill children. The score below 10 indicates a relatively favorable prognosis and lower mortality .

  2. ECMO weaning rate [48 hours]

    The success of ECMO weaning is defined as the survival of patients after ECMO is wean for 48 hours

Eligibility Criteria

Criteria

Ages Eligible for Study:
29 Days to 18 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • Children with severe sepsis and refractory shock admitted to the PICU of four study centers.

The informed consent of the guardians

Exclusion Criteria:
  • active hemorrhage difficult catheter placing Irreversible brain damage patients enrolled in other clinic trial

Contacts and Locations

Locations

Site City State Country Postal Code
1 Children'S Hosptial of Fudan University Shanghai China

Sponsors and Collaborators

  • Guoping Lu
  • Shanghai Children's Hospital
  • Shanghai Children's Medical Center
  • Xinhua Hospital, Shanghai Jiao Tong University School of Medicine

Investigators

  • Principal Investigator: Guoping LU, doctor, Children's Hospital of Fundan University

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Guoping Lu, Director of pediatric Emergency and Critical Care Center. Children's Hospital Fudan University;Director of AHA Training Center for pediatric life support. Children's Hospital Fudan University, Children's Hospital of Fudan University
ClinicalTrials.gov Identifier:
NCT03654287
Other Study ID Numbers:
  • fdpicu-02
First Posted:
Aug 31, 2018
Last Update Posted:
May 8, 2019
Last Verified:
May 1, 2019
Individual Participant Data (IPD) Sharing Statement:
Undecided
Plan to Share IPD:
Undecided
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by Guoping Lu, Director of pediatric Emergency and Critical Care Center. Children's Hospital Fudan University;Director of AHA Training Center for pediatric life support. Children's Hospital Fudan University, Children's Hospital of Fudan University
Additional relevant MeSH terms:

Study Results

No Results Posted as of May 8, 2019